Jarrad Mattieu Aguirre sold $3,642 of LYEL
Chief Medical Officer at Lyell Immunopharma, Inc.. 422 shares at an average of $8.63, traded Oct 12, 2026, filed Oct 13, 2026.
Score components
This filing reached EDGAR on Oct 13, 2026, so its score and components open to free visitors on Oct 20, 2026. The trade itself, the rows in the filing and the price context are public now.
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002150331-26-000003, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 12, 2026 | SOpen-market sale Common Stock | -422 | $8.63 | $3,642 | 19,857 | 19 h ago |
Related signals
Other insiders at Lyell Immunopharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | LYELsell Lyell Immunopharma, Inc. | David Shook Chief Medical Officer | $6,350 500 shares | -2% | |
| 35Weak | Lyell Immunopharma, Inc. | Stephen J. Hill Chief Operating Officer | $15k 989 shares | -6% | |
| 30Weak | Lyell Immunopharma, Inc. | Gary K. Lee Chief Scientific Officer | $23k 1,457 shares | -8% | |
| 56Moderate | Lyell Immunopharma, Inc. | Lynn Seely President and CEO | $149k 9,589 shares | -13% | |
| 30Weak | Lyell Immunopharma, Inc. | Veronica Sanchez Bulis VP, Corporate Controller | $8,905 621 shares | -4% | |
| 35Weak | Lyell Immunopharma, Inc. | Stephen J. Hill Chief Operating Officer | $1,276 89 shares | -0% | |
| 30Weak | Lyell Immunopharma, Inc. | Gary K. Lee Chief Scientific Officer | $1,879 131 shares | -1% | |
| 40Moderate | Lyell Immunopharma, Inc. | Lynn Seely President and CEO | $5,593 390 shares | -1% | |
| 0Weak | Lyell Immunopharma, Inc. | Innovative Cellular Therapeutics Holdings Ltd owner | $137 10 shares | -0% | |
| 0Weak | Lyell Immunopharma, Inc. | Innovative Cellular Therapeutics Holdings Ltd owner | $137 10 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.